Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles M Perou

Showing results (341-350 of 447) with videos related to

Pageof 45
Sort By:
Oncoimmunology|November 3, 2018
Tumor mutational burden is a determinant of immune-mediated survival in breast cancerAlexandra Thomas, Eric D Routh, Ashok Pullikuth, et al.
The Journal of Clinical Investigation|October 24, 2023
Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerNa Zhao, Elena B Kabotyanski, Alexander B Saltzman, et al.
Nature Communications|July 18, 2023
Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancerZhe Jiang, YoungJun Ju, Amjad Ali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without LapatinibLisa A Carey, Donald A Berry, Constance T Cirrincione, et al.
Journal of the National Cancer Institute|September 2, 2017
Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer StudyMelissa A Troester, Xuezheng Sun, Emma H Allott, et al.
JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerNa Zhao, Elena B Kabotyanski, Alexander B Saltzman, et al.
Breast Cancer Research and Treatment|December 7, 2024
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancerVishnu Prasath, Hinda Boutrid, Robert Wesolowski, et al.
JAMA Oncology|May 5, 2017
Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome AtlasDezheng Huo, Hai Hu, Suhn K Rhie, et al.
Nature|February 8, 2018
Asparagine bioavailability governs metastasis in a model of breast cancerSimon R V Knott, Elvin Wagenblast, Showkhin Khan, et al.
Pageof 45

Showing results (341-350 of 447) with videos related to

Sort By:
Pageof 45
Oncoimmunology|November 3, 2018
Tumor mutational burden is a determinant of immune-mediated survival in breast cancerAlexandra Thomas, Eric D Routh, Ashok Pullikuth, et al.
The Journal of Clinical Investigation|October 24, 2023
Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerNa Zhao, Elena B Kabotyanski, Alexander B Saltzman, et al.
Nature Communications|July 18, 2023
Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancerZhe Jiang, YoungJun Ju, Amjad Ali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without LapatinibLisa A Carey, Donald A Berry, Constance T Cirrincione, et al.
Journal of the National Cancer Institute|September 2, 2017
Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer StudyMelissa A Troester, Xuezheng Sun, Emma H Allott, et al.
JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerNa Zhao, Elena B Kabotyanski, Alexander B Saltzman, et al.
Breast Cancer Research and Treatment|December 7, 2024
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancerVishnu Prasath, Hinda Boutrid, Robert Wesolowski, et al.
JAMA Oncology|May 5, 2017
Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome AtlasDezheng Huo, Hai Hu, Suhn K Rhie, et al.
Nature|February 8, 2018
Asparagine bioavailability governs metastasis in a model of breast cancerSimon R V Knott, Elvin Wagenblast, Showkhin Khan, et al.
Pageof 45